An observational study in Mild Cognitive Impairment, Alzheimer Disease, Late Onset and Cognitive Impairment, sponsored by Norwegian University of Science and Technology. Recruiting at 1 site in Norway. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Norwegian University of Science and Technology · Observational
The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD).
The main questions the study aims to answer are:
Participants will undergo:
The projects aims to map brain changes in patients with mild cognitive impairment (MCI) and Alzheimer's Disease (AD) by combining different assesment modalities.
In the MRI, researchers will get the opportunity to analyse both structural and functional brain changes. In the EEG, changes in elctrical activites will be measured. The blood samples allow researchers to analyse specific dementia and inflammation proteins, while fecal speciments can be used to assess bacterial composition. Additionally, the cognitive testing allow to assess the specific part of cognitive function which is affected.
3,872 studies on the registry are indexed under Cognitive Dysfunction; 1,119 are open to participants now.
This study's planned enrollment of 60 is below the median of 150 across 997 observational studies indexed under Cognitive Dysfunction.
Browse Cognitive Dysfunction studies →Norwegian University of Science and Technology is the lead sponsor of 495 studies on the registry; 48 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population is from Tronderlag in Norway, mainly in and around Trondheim city.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Recruitment according to relevant clinical assessment and ICD-criterias.
Device: MRI Scanning · Device: 64-channel EEG · Device: Polysomnography · Biological: Blood samples · Biological: Fecal samples · Behavioral: Cognitive tests
Recruitment according to relevant clinical assessment and ICD-criterias.
Device: MRI Scanning · Device: 64-channel EEG · Device: Polysomnography · Biological: Blood samples · Biological: Fecal samples · Behavioral: Cognitive tests
Equivalent number of research participants as in the MCI and mild AD group.
Device: MRI Scanning · Device: 64-channel EEG · Device: Polysomnography · Biological: Blood samples · Biological: Fecal samples · Behavioral: Cognitive tests
MRI scanning with volumetric, resting and activity-based sequences.
EEG to quantifiy electric activity.
A randomized group will undergo polysomnography.
Analysis of specific blood biomarkers.
Analysis of bacterial composition.
Interview-based cognitive tests for assesment of cognitive levels.
MCI-AD converters
Identify biomarker profiles unique for patients with MCI that develop AD for earlier prediction.
Time frame: 5 years
AD-subclassification
Identify biomarker profiles that can assist in a more thorough AD-classification
Time frame: 5 years
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Norwegian University of Science and Technology →